Loading clinical trials...
Loading clinical trials...
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Against Systemic Corticotherapy in Patients Admitted by Covid-19 With Bilateral Pneumonia and Poor Evolution
Conditions
Interventions
Tociliziumab group
Methylprednisolone group
Locations
1
Spain
Clinical Research Platform Biodonostia Health Research Institute
San Sebastián, Guipuzcoa, Spain
Start Date
September 3, 2020
Primary Completion Date
July 31, 2021
Completion Date
October 31, 2021
Last Updated
August 12, 2021
NCT06927622
NCT05531032
NCT04466098
NCT04930874
NCT05077917
NCT04821934
Lead Sponsor
Biogipuzkoa Health Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions